ivabradine / Generic mfg. - LARVOL DELTA

Ivabradine Use and Exercise Capacity Post-Atrial Switch Repair for Transposition of Great Arteries. (PubMed, JACC Adv) - P2/3 | "Ivabradine use in patients with transposition of the great arteries and atrial switch repair lowered peak heart rate with exercise and was associated with a higher oxygen pulse. (Effect of Ivabradine use on exercise capacity in patients with transposition of the great arteries [TGA] post atrial switch repair; ACTRN12621000196842)."

Clinical • Journal • Cardiovascular

Eco-friendly stability-indicating chromatographic methods with integrated molecular docking and ADMET evaluation for simultaneous determination of carvedilol and ivabradine. (PubMed, J Chromatogr Sci) - "Moreover, statistical comparison of the proposed methods with reported and official methods was conducted. Additionally, structure elucidation, molecular docking and ADMET assessment of the degradates were successfully performed."

Journal • Cardiovascular

Early administration of ivabradine in patients with acute anterior ST-elevation myocardial infarction: a prospective, randomized, open-label study on in-hospital and short-term major adverse cardiac events and left ventricular function. (PubMed, Egypt Heart J) - "Early administration of ivabradine in patients with acute anterior STEMI and elevated HR without cardiogenic shock was associated with better heart-rate control and favorable short-term echocardiographic outcomes, while the clinical outcome findings require confirmation in prospectively registered, adequately powered multicenter trials. These findings apply to Killip class I-III patients; Killip class IV patients (cardiogenic shock) were excluded from this study."

Adverse events • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Single-cell profiling reveals context-dependent immune regulation shared by sepsis and systemic lupus erythematosus. (PubMed, Front Immunol) - "Shared candidate genes were characterized using protein-protein interaction and enrichment analyses, and prioritized candidates were subsequently selected using an integrated multi-dimensional evidence framework combining discovery-stage differential expression and orthogonal supporting evidence.Single-cell RNA sequencing (scRNA-seq) analysis was performed on five in-house samples (normal, SIRS, and sepsis) and integrated with external datasets (GSE167363 for sepsis; GSE162577 and GSE136035 for SLE) using Harmony...Furthermore, SIGLEC1 knockdown attenuated LPS-induced IL-6 and TNF-α production and reduced the CD86-positive macrophage phenotype, providing functional evidence for its involvement in macrophage inflammatory responses. SIGLEC1 and TRIM25 are context-dependent immune signatures in sepsis and SLE, with loss-of-function evidence supporting SIGLEC1 in macrophage inflammatory responses."

Journal • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Septic Shock • Systemic Lupus Erythematosus • CD86 • IL6 • SIGLEC1 • TNFA

Heart Failure Pharmacotherapy and Long-Term Outcomes After Extracorporeal Membrane Oxygenation: A Nationwide Real-World Cohort Study. (PubMed, Int J Gen Med) - "Use shifted from angiotensin-converting enzyme inhibitors and digoxin toward angiotensin receptor blockers, beta-blockers, sodium-glucose cotransporter 2 inhibitors, and ivabradine. Among 6-month survivors of cardiogenic ECMO, a high-risk and clinically unique population often excluded from HF trials, post-discharge HF pharmacotherapy was associated with lower long-term mortality. These findings support structured cardiovascular reassessment and individualized HF medication review after ECMO."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Microaxial Flow Pump and Ivabradine for Tachycardia-Induced Cardiogenic Shock Caused by Automatic Atrial Tachycardia. (PubMed, JACC Case Rep) - "A microaxial flow pump may provide hemodynamic support, facilitating safe rate control and myocardial recovery in TIC complicated by cardiogenic shock. Ivabradine may be useful when beta-blockers are difficult to initiate."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure

Vital Sign Profiles Following Single Dose Ivabradine in the Pediatric Cardiac Critical Care Unit (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Critical care • Pediatrics

Efficacy and Safety of Ivabradine versus Beta Blockers in Inappropriate Sinus Tachycardia: A Systematic Review and Meta-Analysis (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular

IRISS: Ivabradine for Heart Rate Control In Septic Shock (clinicaltrials.gov) - P3 | N=429 | Completed | Sponsor: Assistance Publique - Hpitaux de Paris | Active, not recruiting ➔ Completed

Trial completion • Congestive Heart Failure • Septic Shock

Preoperative Ivabradine Doses for Hemodynamic Stability in FESS (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Minia University

New trial • Otorhinolaryngology

Does evidence-based treatment recommendations implementation improve 1-year outcomes in patients with heart failure? (ESC 2026) - "In terms of treatment, there was a significant reduction in the use of diuretics, digoxin, ivabradine and ACEI/ARB, and a very significant increase in ARNI, MRA, SGLT2 inhibitors and potassium chelators (Figure 1). In our contemporary cohort of real-life HF patients, the use of ARNI, SGLT2 inhibitors and MRAs increased very markedly from 2019 to 2024, reflecting a rapid implementation of clinical practice guideline recommendations. However, this was not associated with a reduction in mortality or HF decompensations, despite a lower severity profile of HF in the most recent period. The reasons for this discrepancy should be carefully analyzed."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Association between up-titration of guideline-directed medical therapy and clinical outcomes in patients with chronic heart failure with reduced ejection fraction (ESC 2026) - "The GDMT score was calculated based on the use and dose of the quadruple therapy, ivabradine, vericiguat, and hydralazine/nitrates (Figure 1).1 Patients were classified into an up-titration group or a no up-titration group according to the change in GDMT score from baseline to 9 months after enrolment. In patients with HFrEF, up-titration of GDMT was independently associated with favourable clinical outcomes and LVRR. The GDMT score could facilitate optimisation of GDMT even in patients with chronic HFrEF."

Clinical • Clinical data • Cardiovascular • Congestive Heart Failure • Heart Failure

The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial (ESC 2026) - "In patients with HFrEF and obesity on optimal GDMT, liraglutide significantly reduced HF hospitalizations and improved quality of life, with neutral mortality and manageable heart rate effects. Although additional pharmacotherapy for rate control was required—ivabradine in sinus tachycardia and intensified beta-blockade in AF—the net clinical benefit supports liraglutide as a safe adjunctive therapy in this population."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Ivabradine in cardiogenic shock with catecholamine weaning failure: focus on the atrial fibrillation subpopulation (ESC 2026) - "Among patients with cardiogenic shock and prior catecholamine weaning failure, the atrial fibrillation subpopulation demonstrated significant heart rate reduction and improvement in stroke volume and ventriculo-arterial coupling after ivabradine initiation, without deterioration of arterial pressure or vascular resistance. These findings suggest that ivabradine may be hemodynamically safe and potentially beneficial even in selected CS patients with atrial fibrillation, warranting further prospective investigation"

Clinical • Atrial Fibrillation • Cardiovascular

Ivabradine for hemodynamic optimization and catecholamine weaning in cardiogenic shock: a retrospective cohort study (ESC 2026) - " The median dobutamine dose at the time of ivabradine introduction was 8 μg/kg/min. In this single-center retrospective study, ivabradine safely improved hemodynamic parameters and ventriculo-arterial coupling, facilitating catecholamine withdrawal in the majority of patients with cardiogenic shock and prior weaning failure. These findings support further prospective evaluation of ivabradine in this high-risk population"

Retrospective data • Cardiovascular

A "monstrous" conflict of interest: Kim Fox, ivabradine, and European Society of Cardiology clinical practice guidelines. (PubMed, BMJ) - No abstract available

Clinical guideline • Journal • Cardiovascular

From alert to harm: a time-to-event analysis of clinical decision support activation and adverse drug events in critical cardiac patients (ESC 2026) - "Rapid-onset ADEs were predominantly: Ticagrelor + Enoxaparin/Aspirin (major bleeding) and Ivabradine + QT-prolonging drugs (QTc prolongation, arrhythmia). Delayed ADEs (>72 hours) were often associated with chronic drug combinations or cumulative toxicity (e.g., Digoxin + Beta Blockers)... The temporal relationship between CDSS alerts and ADE occurrence identifies a critical “window of opportunity” for intervention. Timing-based alert prioritization could reduce alert fatigue, improve clinical responsiveness, and prevent high-risk ADEs in CCCU patients. These findings provide actionable guidance for the next-generation CDSS design, integrating both alert severity and expected onset timing of ADEs."

Adverse events • Clinical • Cardiovascular

Postural Orthostatic Tachycardia Syndrome (POTS): A Review. (PubMed, JAMA) - "Pharmacological therapies should be individualized and may include β-blockers, ivabradine, midodrine, fludrocortisone, and pyridostigmine, although evidence supporting many therapeutic interventions is limited by small studies and lack of large, randomized trials. POTS is a chronic autonomic disorder associated with functional impairment and reduced quality of life that is diagnosed based on characteristic orthostatic symptoms in the absence of orthostatic hypotension after excluding alternative causes of sinus tachycardia. Treatment involves nonpharmacological measures (such as increased fluid and sodium intake), lower-body compression garments, structured exercise training, and individualized pharmacological therapy."

Journal • Anorexia • Cardiomyopathy • Cardiovascular • CNS Disorders • Cognitive Disorders • Constipation • Endocrine Disorders • Epstein-Barr Virus Infections • Fatigue • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hypotension • Infectious Disease • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pulmonary Disease • Renal Disease • Respiratory Diseases • Sleep Disorder • Solid Tumor

IVAMUS: Effect of Ivabradine use on exercise capacity in patients with transposition of the great arteries (TGA) post atrial switch repair (ANZCTR) - P2/3 | N=20 | Completed | Sponsor: Melbourne Health | Recruiting ➔ Completed

Trial completion • Cardiovascular • Heart Failure

Comparative Efficacy and Safety of Ivabradine vs. Beta Blockers in Heart Transplant Patients: A Systematic Review and Meta-Analysis. (PubMed, Health Sci Rep) - "Given the small evidence base, the predominance of observational studies, and the substantial heterogeneity observed across several outcomes, these findings should be regarded as exploratory and hypothesis-generating. Further large-scale RCTs are warranted to confirm these findings and guide clinical decision-making."

Journal • Retrospective data • Review • Fatigue • Infectious Disease • Septic Shock • Transplantation

Persistent Cognitive Dysfunction in Postural Orthostatic Tachycardia Syndrome: A Scoping Review of Neural Mechanisms, Interventions, and Critical Research Gaps. (PubMed, Cureus) - "Current therapies, including beta-blockers, ivabradine, midodrine, exercise, salt and fluid loading, compression garments, cognitive behavioral therapy (CBT), and sleep management, rarely use cognition as a primary endpoint. Findings suggest that persistent cognitive dysfunction in POTS may reflect incomplete alignment between neurological mechanisms and cardiovascular-centered care, requiring validated cognitive outcomes and multimodal trials combining biological, autonomic, and rehabilitative interventions."

Journal • Review • Cardiovascular • Cognitive Disorders • Immunology • Inflammation

Propranolol and Ivabradine Are Equally Effective in POTS But Not Equipoise in Real Life. (PubMed, JACC Adv) - No abstract available

Journal

Effect of atenolol versus ivabradine on heart rate variability in patients of schizophrenia with clozapine-induced tachycardia: a randomized controlled trial. (PubMed, Psychiatry Res) - P=N/A | "No significant between-group differences in HRV parameters were established between atenolol and ivabradine. Ivabradine could be a viable option in patients where atenolol is either contraindicated or not tolerated. Future larger multicentric studies are needed for greater generalisability."

Journal • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia

Beyond Heart Rate: Interpreting the Hemodynamic Response to Ivabradine in Pediatric Cardiac Critical Care. (PubMed, Am J Ther) - No abstract available

Journal • Critical care • Pediatrics

Ivabradine alleviates the cisplatin-induced cardiotoxicity in rats through regulating the crosstalk between MLCP/PKG, MEK/ERK pathways and miRNA-34a levels. (PubMed, Immunopharmacol Immunotoxicol) - "Furthermore, its impact on cardiac tissue viability was supported by increased B-cell lymphoma 2 (Bcl2) levels and decreased caspase-3 staining in immunohistopathology. IVA may significantly mitigate cardiac injury in Cis-induced cardiotoxicity through regulating multiple pathways and miRNA-34a levels."

IO biomarker • Journal • Preclinical • B Cell Lymphoma • Cardiovascular • Fibrosarcoma • Lymphoma • Oncology • Sarcoma • Solid Tumor • BCL2 • CASP3 • IL10 • IL1B • IL6 • MIR34A • NOS3 • PRKCE • TNFA